KENNETH BATE - 16 Jun 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Brian Lynch, as attorney-in-fact for Kenneth Bate
Issuer symbol
MDGL
Transactions as of
16 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 06:30:29 UTC
Previous filing
21 Jun 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award $0 +9,470 $0.000000 9,470 16 Jun 2022 Common Stock 9,470 $65.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.